| Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder. | |
| | |
MedLine Citation:
|
PMID: 20969642 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate the efficacy of extended-release (ER) tolterodine 4mg/day for the treatment of neurogenic detrusor overactivity (NDO) and/or low-compliance bladder by assessing urodynamic parameters. METHODS: Forty-six patients (25 male, 21 female; mean age 57.6±20.7years) with NDO (n=39) and/or low-compliance bladder (n=7) were included in this 12-week single-arm study. Twenty-one patients (46%) were on clean intermittent catheterization and other patients could void on their own. A video urodynamic study was performed before and at 3 months after treatment. Changes in Overactive Bladder Symptom Score (OABSS), International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), and King's Health Questionnaire (KHQ) as well as changes in number of voids, amount of each void, and number of leaks in 24h according to the 3-day voiding diary were also evaluated before treatment and at weeks 4 and 12 after treatment. RESULTS: Bladder capacity at first sensation and maximum cystometric capacity increased significantly, by an average of 36.8mL (P=0.0402) and 82.3mL (P<0.0001), respectively. Maximum cystometric capacity increased by more than 50mL in 19 patients (49%) following treatment. Detrusor overactivity disappeared in three of 32 patients (9%), bladder capacity at first involuntary contraction increased significantly (P=0.0009), and amplitude of detrusor overactivity decreased significantly (P=0.0025). In patients with low-compliance bladder, bladder compliance increased significantly (P=0.0156). Overactive bladder symptom score, International Consultation on Incontinence Questionnaire-Short Form score, number of voids (per 24h and night-time), number of urgency episodes in 24h, number and amount of leaks in 24h, and amount of mean and maximum voided volumes all decreased significantly after treatment. CONCLUSION: Tolterodine is effective and well tolerated for the treatment of NDO and/or low-compliance bladder in patients with neurogenic bladder. |
| | |
Authors:
|
Miho Watanabe; Tomonori Yamanishi; Mikihiko Honda; Ryuji Sakakibara; Tomoyuki Uchiyama; Ken-Ichiro Yoshida |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-10-04 |
Journal Detail:
|
Title: International journal of urology : official journal of the Japanese Urological Association Volume: 17 ISSN: 1442-2042 ISO Abbreviation: Int. J. Urol. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9440237 Medline TA: Int J Urol Country: Australia |
Other Details:
|
Languages: eng Pagination: 931-6 Citation Subset: IM |
Copyright Information:
|
© 2010 The Japanese Urological Association. |
Affiliation:
|
Department of Urology, Dokkyo Medical University, Mibu, Tochigi Department of Neurology, Sakura Medical Center, Toho University, Sakura Department of Neurology, Chiba University, Chiba, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Transurethral resection of the prostate immediately after high-intensity focused ultrasound treatmen...
Next Document: Tissue engineering and stem cells: basic principles and applications in urology.